If you have been reading about research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
The FDA has not approved any acellular dermal matrix products for use in implant-based breast reconstruction following surgery to remove a breast tumour, as the published literature suggests that different ADM products may have different risk profiles, thus clinical results may not be consistent.
However, this final plan was prevented by the fall of the Peruvian Dictatorship of Bolívar in 1827, the Peruvian Intervention in Bolivia in 1828 for the fall of Sucre, and later the Dissolution of Gran Colombia after the Gran Colombian-Peruvian War. Not without Bolívar previously accusing the populations of Peru and Bolivia as "the despicable peoples of the South who allowed themselves to be drawn into the civil war or were seduced by the enemies."Finally, the antecedents of the Gran Colombo-Peruvian War are considered by many historians as the maximum evidence of Bolívar's anti-Peruvianism. It is reported that his acts of government left much to be desired and were even harmful to the Peruvian indigenous population, for which he imprisoned or shot guerrillas who had helped him in the campaigns in the mountains. To the indigenous people, to whom he dedicated his worst insults, he reimposed the indigenous tribute (which had been abolished in the viceroyalty with the constitution of Cádiz) and weakened their peasant communities with the abolition of the Cacicazgos in the young Republic of Peru, breaking thus definitively a hierarchical system of the Inca nobility that had been present, for more than 3 centuries in Peru, for the protection of the economic interests of the Indian against a nascent Gamonalismo.
== Mission and Research Strategy == The mission of TBRI is targeted towards the control, the diagnosis and management of endemic diseases and their complications especially those affecting the liver, the gastrointestinal and the urinary tracts, mainly as result of schistosomiasis and viral hepatitis, this is to meet the social, economic and technological needs of Egypt and the regional area. The Institute adopts an integrated strategy based on six research programs that can cope with and fulfill this objective:
MEB-1170 is an atypical opioid receptor modulator which is under development for the treatment of pain and opioid use disorder. It is a highly biased agonist of the μ-opioid receptor (MOR) and appears to be biased for activation of G protein signaling over β-arrestin recruitment. Aside from the fact that it is a MOR biased agonist, the drug is said to be a MOR full agonist as well as a κ-opioid receptor (KOR) partial agonist and to have a unique pharmacological profile. It is taken orally. The drug produces robust analgesia in several assays similarly to morphine in rodents. However, in contrast to other MOR agonists like morphine and oliceridine, MEB-1170 is said to have not produced analgesic tolerance, sedation, respiratory depression, rewarding effects, or reinforcing effects and to have shown only minimal withdrawal symptoms. In addition, unlike morphine, but similarly to oliceridine, it negligibly affected gastrointestinal transit, a measure of constipation-like effect. As such, the drug is claimed to have greatly improved tolerability, safety, and misuse liability relative to conventional opioids like morphine. The toxicokinetics of MEB-1170 in rats and dogs have been described. It has a longer duration than morphine in rodents. MEB-1170 was first described in the news media in 2017 and in the scientific literature in 2018. It is being developed by Mebias Discovery. As of April 2023, the drug is in phase 1 clinical trials for treatment of pain and opioid use disorder. It is being developed for both prevention and treatment of opioid use disorder.
Sources: en.wikipedia.org
) which are the radial, tangential and longitudinal dimensions respectively, in inches, with the longitudinal dimension divided by ten because water diffuses about 10 times more rapidly in the longitudinal direction (along the grain) than in the lateral dimensions. The solution to the above equation is:
== Variants == The electrosprays operated at low flow rates generate much smaller initial droplets, which ensure improved ionization efficiency. In 1993 Gale and Richard D. Smith reported significant sensitivity increases could be achieved using lower flow rates, and down to 200 nL/min. In 1994, two research groups coined the name micro-electrospray (microspray) for electrosprays working at low flow rates. Emmett and Caprioli demonstrated improved performance for HPLC-MS analyses when the electrospray was operated at 300–800 nL/min. Wilm and Mann demonstrated that a capillary flow of ~ 25 nL/min can sustain an electrospray at the tip of emitters fabricated by pulling glass capillaries to a few micrometers. The latter was renamed nano-electrospray (nanospray) in 1996. Currently the name nanospray is also in use for electrosprays fed by pumps at low flow rates, not only for self-fed electrosprays. Although there may not be a well-defined flow rate range for electrospray, microspray, and nano-electrospray, studied "changes in analyte partition during droplet fission prior to ion release". In this paper, they compare results obtained by three other groups. and then measure the signal intensity ratio [Ba2+ + Ba+]/[BaBr+] at different flow rates. Cold spray ionization is a form of electrospray in which the solution containing the sample is forced through a small cold capillary (10–80 °C) into an electric field to create a fine mist of cold charged droplets.
== Chemistry == Adrenaline, also known as 3,4,β-trihydroxy-N-methylphenethylamine, is a substituted phenethylamine and catecholamine. It is the N-methylated analogue of norepinephrine (noradrenaline; 3,4,β-trihydroxyphenethylamine) and the N-methylated and β-hydroxylated analogue of dopamine (3,4-dihydroxyphenethylamine). Its chemical composition is Nonacarbon Tridecahydrogen Nitrogen Trioxygen (C9H13NO3).
Sources: en.wikipedia.org
Hibiscus was a London restaurant which was owned and run by French chef Claude Bosi. It was opened in 2000 in Ludlow, Shropshire, and won its first Michelin star within a year, and a second in the 2004 Guide. In July 2006, Bosi and his wife Claire announced that they were to sell the location in Ludlow and move closer to London. The property was sold to Alan Murchison, and Bosi purchased a new site on Maddox Street in London. The restaurant closed in 2016. Bosi used molecular gastronomy to create some items on the menu in an effort to enhance their flavours, such as freeze-drying cabbage to create a purée. The restaurant has received mixed reviews from critics, but has been listed in The World's 50 Best Restaurants since 2010, and was named by Egon Ronay as the best restaurant in the UK in 2005. The Good Food Guide ranked Hibiscus as the eighth-best restaurant in the UK in the 2013 edition. It has also been awarded five AA Rosettes.
Acanthosis nigricans is a cutaneous finding characterized by brown-to-black, velvety hyperpigmentation of the skin, most often affecting body folds such as the posterior neck, axillae, groin and umbilicus. It is strongly associated with insulin resistance and hyperinsulinaemia, including in type 2 diabetes and metabolic syndrome. Excess insulin activates insulin and insulin-like growth factor signalling pathways, stimulating proliferation of keratinocytes and fibroblasts and producing the characteristic plaques. Acanthosis nigricans may also occur in hereditary syndromes, as a reaction to medications, or as a paraneoplastic syndrome associated with internal malignancy. In children, it is an important clinical marker of metabolic and cardiometabolic risk.
Tofu, made from soy/soybeans. Textured vegetable protein – a defatted soy flour product that is a by-product of extracting soybean oil. It is often used as a meat analogue or meat extender. It is quick to cook, with a protein content that is comparable to certain meats. Ganmodoki – a traditional Japanese tofu based dish similar to veggie burgers Tempeh – a traditional Indonesian soy product in a cake form, made from fermented soybeans
Surf City Squeeze was started in the early 1980s by Kevin Blackwell and his wife Kathi, and later became a franchise. Later, in 1998/1999, Sports Group International, Inc. (a company that was originally formed to distributed Spalding-branded sports drinks) merged with Surf City Squeeze with Surf City Squeeze's management taking over full control of the company. Also in 1999, Sports Group International purchased Frullati Cafe & Bakery Chain, bringing the total number of its franchised locations to 200. In 2001, Kevin Blackwell changed the name of his company from Sports Group International to Kahala Corp. after terminating an agreement with Spalding. Also in 2000, Kahala Corp. then developed the Rollerz brand. From 2002 to 2006, Kahala Corp. purchased Ranch One Grilled Chicken, Samurai Sam's Teriyaki Grill, Taco Time, Great Steak, Johnnie's New York Pizzeria, and Blimpie. Kahala also acquired the license to Wafflo. In 2007, Kahala Corp and Cold Stone Creamery agreed to merge creating a combined company holding 13 diversified brands. The combined company generated more than $1.1 billion in system wide sales in partnership with 3,000-plus franchisees and more than 4,600 retail locations. As a result of the merger, Kahala's CEO Kevin Blackwell and Cold Stone Creamery's CEO and chairman Doug Ducey were respectively appointed chairman and CEO of the new combined company, Kahala-Cold Stone. Ducey left a few months later to join tech start-up iMemories after being forced out by Blackwell. In July 2007, Kahala-Cold Stone acquired Cereality Cereal Bar & Cafe.
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.